Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drug

Alembic Pharmaceuticals has secured final approval from the USFDA for its generic Dasatinib tablets. These tablets are used to treat certain blood cancers in adults and children. The approval covers multiple strengths of the drug. Dasatinib is a vital medication for patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2v3le85
via IFTTT